Brief: Lantern Pharma And Starlight Therapeutics Announce FDA Clearance Of Ind For A Planned Phase 1 Pediatric Cns Cancer Trial Of Star-001
27/03/2026 11:52
Lantern Pharma Inc LTRN.O: LANTERN PHARMA AND STARLIGHT THERAPEUTICS ANNOUNCE FDA CLEARANCE OF IND FOR A PLANNED PHASE 1 PEDIATRIC CNS CANCER TRIAL OF STAR-001 LANTERN PHARMA INC - TRIAL TO EVALUATE STAR-001 ALONE AND WITH SPIRONOLACTONE IN PEDIATRIC CNS CANCERS LANTERN PHARMA INC - TRIAL PLANNED WITH POETIC CONSORTIUM ACROSS 14 CANCER CENTERS IN US, CANADA, ISRAEL Source text: ID:nBw5fY5r7a Further company coverage: LTRN.O
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview